We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597120

CAS#: 8058-79-5

Description: Paraprost consists of 1-glutamic acid, alanine & glycine; used in prostate hypertrophy drug therapy.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-07-11. Prices are subject to change without notice.

Paraprost is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 597120
Name: Paraprost
CAS#: 8058-79-5
Chemical Formula: C10H21N3O8
Exact Mass:
Molecular Weight: 311.29
Elemental Analysis: C, 38.58; H, 6.80; N, 13.50; O, 41.12

Synonym: Paraprost;

IUPAC/Chemical Name: L-alanine compound with L-glutamic acid and glycine (1:1:1)


InChi Code: InChI=1S/C5H9NO4.C3H7NO2.C2H5NO2/c6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;3-1-2(4)5/h3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1,3H2,(H,4,5)/t3-;2-;/m00./s1

SMILES Code: N[C@@H](CCC(O)=O)C(O)=O.N[C@@H](C)C(O)=O.NCC(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. WITHDRAWN: Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2011 May 11;(5):CD001042. doi: 10.1002/14651858.CD001042.pub2. Review. PubMed PMID: 21563128.

2: Okada H. [BPH pharmacotherapy (miscellaneous)]. Nihon Rinsho. 2002 Dec;60 Suppl 11:367-72. Review. Japanese. PubMed PMID: 12599602.

3: Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001042. Review. Update in: Cochrane Database Syst Rev. 2011;(5):CD001042. PubMed PMID: 10796739.

4: MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000 May;85(7):836-41. Review. PubMed PMID: 10792162.

5: Mahoney JE. Plant extracts in the medical management of benign prostatic hyperplasia: fact or fiction? Can J Urol. 1995 May;2(2):125-9. PubMed PMID: 12803719.

6: Kumamoto Y, Tsukamoto T, Yachiku S, Kaneko S, Koyanagi T, Togashi M, Maru A, Tsuchida S, Nishizawa O, Orikasa S, et al. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy]. Hinyokika Kiyo. 1990 Oct;36(10):1213-32. Japanese. PubMed PMID: 1702262.

7: Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, Okajima E, Hirao Y, Ohzono S, Shimada K, et al. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost]. Hinyokika Kiyo. 1990 Apr;36(4):495-516. Japanese. PubMed PMID: 1696065.

8: Yamaguchi O, Shiraiwa Y, Kobayashi M, Yokota T, Ohinata M, Aoki H, Tsuzuki T, Ohori M. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. Urol Int. 1990;45 Suppl 1:40-6. PubMed PMID: 1690481.

9: Aito K, Watsubo E. [The conservative treatment of prostatic hypertrophy with Paraprost]. Hinyokika Kiyo. 1972 Jan;18(1):41-4. Japanese. PubMed PMID: 4112552.